For research use only
| Cat No. | ABC-TC508S |
| Product Type | Human Esophageal Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Esophagus |
| Product Code | Eca109; Eca 109; EC-109; EC109 |
EC-109: Tumorigenic human esophageal squamous cell carcinoma cell line. Epithelial-like, adherent growth.
EC-109 (Eca-109) is a human epithelial cell line established in 1973 from a middle-esophageal squamous cell carcinoma of a female Chinese patient. These cells grow adherently as monolayers exhibiting polygonal morphology and can be continuously passaged, with a doubling time of approximately 28.6 hours. EC-109 cells express epithelial markers such as cytokeratins and EpCAM (CD326), reflecting their esophageal epithelial origin. They show enrichment of genes involved in key pathways including cell cycle regulation, TP53, Hippo, and Wnt signaling. Harboring molecular alterations typical of esophageal squamous cell carcinoma, EC-109 cells are tumorigenic in BALB/c nude mice. This cell line is widely employed to study cancer cell behaviors such as proliferation, migration and invasion, apoptosis, autophagy modulation, and drug sensitivity—including models of paclitaxel resistance—making it a valuable preclinical model for esophageal cancer research.
| Product Code | Eca109; Eca 109; EC-109; EC109 |
| Species | Human |
| Cat.No | ABC-TC508S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Esophagus |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Esophageal Cancer Cell Lines |
The EC-109 esophageal squamous cell carcinoma line enables research across esophageal cancer mechanisms, pathophysiology, and drug resistance. It facilitates drug sensitivity studies to identify therapeutics and resistance mechanisms, molecular biology investigations of genetic alterations and biomarkers, and behavioral assays assessing proliferation, migration, and invasion. Additionally, EC-109 supports preclinical drug screening for novel compounds and immunocytochemical biomarker analysis for diagnostic/prognostic marker identification.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
